Mondrian Investment Partners LTD Acquires 127,357 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Mondrian Investment Partners LTD increased its stake in Thermo Fisher Scientific Inc. by 146.1%, owning 214,506 shares worth approximately $106.74 million as of its recent SEC filing.
• Several institutional investors have significantly increased their investments in Thermo Fisher Scientific, with GAMMA Investing LLC growing its stake by over 60,610% in the first quarter.
• Thermo Fisher Scientific reported $5.36 EPS for the last quarter, exceeding expectations, with a revenue of $10.86 billion, showcasing a 2.9% year-over-year increase.

Mondrian Investment Partners LTD lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 146.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 214,506 shares of the medical research company's stock after buying an additional 127,357 shares during the period. Mondrian Investment Partners LTD owned about 0.06% of Thermo Fisher Scientific worth $106,738,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of TMO. Brighton Jones LLC boosted its position in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares in the last quarter. Bank Pictet & Cie Europe AG raised its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after acquiring an additional 461 shares in the last quarter. Cohen & Steers Inc. raised its holdings in Thermo Fisher Scientific by 5.2% during the fourth quarter. Cohen & Steers Inc. now owns 592 shares of the medical research company's stock worth $308,000 after acquiring an additional 29 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its holdings in Thermo Fisher Scientific by 13.3% during the fourth quarter. CreativeOne Wealth LLC now owns 6,831 shares of the medical research company's stock worth $3,554,000 after acquiring an additional 804 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on TMO shares. Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Raymond James Financial reiterated an "outperform" rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. UBS Group boosted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Finally, Stifel Nicolaus lowered their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $593.00.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 8,000 shares of the firm's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $52,340,824.30. The trade was a 6.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,400 shares of company stock worth $8,345,792 in the last 90 days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $0.83 during midday trading on Thursday, reaching $485.62. The company's stock had a trading volume of 1,955,228 shares, compared to its average volume of 3,096,282. The business's 50 day moving average price is $433.08 and its two-hundred day moving average price is $461.44. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market cap of $183.38 billion, a P/E ratio of 28.09, a P/E/G ratio of 2.59 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company's revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $5.37 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.